Episodic migraine patient profile*

*Episodic migraine was defined as 4 to 14 headache days per month, of which ≥4 were migraine days.1 One month was defined as 28 consecutive days.2

Meet Carol, a fictitious patient with episodic migraine

In patients like Carol, which factor would most likely lead you to consider updating her current treatment regimen?

Here’s how others responded:

Compliance issues

Increased use of acute medications

Busy, working mother

Fear of self-injection

Meet Carol, a fictitious patient with episodic migraine

Meet Carol†‡

†Fictitious patient case.

PATIENT INFORMATION

Age: 35 years old

Sex: Female

Diagnosis: Episodic migraine, 17 years

Mean migraine days per month: 11

Comorbidities: Obesity

TREATMENT HISTORY

Migraine medication use

  • Currently on an oral antiepileptic for migraine prevention
  • Additionally, treating migraine acutely with prescription and over-the-counter oral medications

Concomitant medication use

  • Presently on birth control (IUD)

FACTORS FOR CONSIDERATION

  • Compliance issues with current preventive treatment due to side effects
  • Acute medication use is increasing
  • Her migraine attacks typically last longer than 12 hours
  • Consistently sees her neurologist on a quarterly basis
  • Busy, working mother with two young children—fears she is neglecting her work and family obligations
  • Increased absenteeism and presenteeism
  • Afraid of self-injection

‡This patient profile may represent some of the healthcare challenges that could be encountered during typical clinical practice. Symptoms and responses to any treatment may vary. As always, use your clinical judgement.

Consider VYEPTI for your patients like Carol

With one 30-minute IV infusion every 12 weeks, VYEPTI has the potential to help some patients overcome challenges associated with migraine.1

Learn more about VYEPTI in episodic migraine

You may also be interested in:

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

References:
  1. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
  2. Data on file. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.